News & Updates

In patients with infectious keratitis, Rose Bengal (RB) photodynamic antimicrobial therapy (PDAT) mitigates the need for therapeutic penetrating keratoplasty, as shown in a recent study. However, keratoplasty after RB-PDAT may increase the chances of graft survival at 1 year postoperatively.

New drug applications approved by US FDA as of 01 - 15 August 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The investigational drug soticlestat (TAK-935) helps reduce seizure frequency in children with Dravet syndrome (DS) or Lennox–Gastaut syndrome (LGS), with its safety profile consistent with previous data, according to the results of the phase II ELEKTRA trial.

In childhood cancer survivors (CCS), treatment with vincristine appears to be linked with global longitudinal strain (GLS) abnormalities over the long-term, a new study has found.

Hepatic recruitment of eosinophils appears to play a protective role during acute liver injury caused by acetaminophen overdose, reveals a recent study.

Long-term combination therapy with relugolix plus oestradiol and norethindrone (relugolix-CT) shows sustained reductions in dysmenorrhoea and non-menstrual pelvic pain (NMPP) for up to 2 years in premenopausal women with endometriosis, according to the SPIRIT extension* study presented at ESHRE 2022.

Treatment with the sodium‐glucose cotransporter 2 inhibitor canagliflozin protects against cardiovascular events in patients with comorbid type 2 diabetes (T2D) and chronic kidney disease (CKD), with a larger absolute benefit for total cardiovascular than first cardiovascular events, according to a post hoc analysis.